Amgen stock holds near a 52-week high after Q2 beat
Published on 08/28/2026 at 17:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. (US0311621009) stock opened at $436.99 on August 28, 2026, leaving it just below the 52-week high of $447.03 and above the 200-day moving average of $364.23.
That setup follows second-quarter 2026 results on August 4, 2026, when Amgen reported revenue of $10.05 billion and adjusted EPS of $6.29, both ahead of estimates, while full-year 2026 guidance moved to $22.30 to $23.50 per share.
Q2 numbers still set the tone
Market data shows Amgen at a $236.25 billion market cap with a 52-week range of $269.77 to $447.03 and a 50-day moving average of $386.75, keeping the shares in the upper end of their recent band.
The second-quarter comparison is the key one: revenue rose 9.5 percent from the prior-year period to $10.05 billion, and EPS improved from $6.02 to $6.29, a clear year-over-year gain that helped support the raised outlook.
Consensus sits lower
Recent market overviews place the consensus price target at $380.43 and the consensus recommendation at Hold, which leaves the stock above that average target while still backed by a strong quarterly print and a dividend run rate of $10.08 a share.
That gap matters. With the latest opening price at $436.99, the shares trade $56.56 above the consensus target, so the market is already discounting stronger execution than the average analyst view implies.
Tezspire adds a product angle
Amgen's TEZSPIRE remains a representative product in the portfolio, and recent reporting said the therapy delivered positive Phase 3 results in eosinophilic esophagitis, adding another possible growth path beyond severe asthma.
For a biotech with a $236.25 billion market cap and FY 2026 EPS guidance of $22.30 to $23.50, pipeline data still matters alongside the headline earnings beat.
Stock level and income
Amgen stock remains close to its $447.03 high and well above its $269.77 low, while the quarterly dividend of $2.52 per share points to an annualized $10.08 payout and a 2.3 percent yield.
For investors tracking the name on August 28, 2026, the three figures that matter most are the $436.99 opening price, the $10.05 billion quarterly revenue, and the $6.29 adjusted EPS, all of which frame the stock's current premium.
More on Amgen stock
Amgen's portfolio is built around biologics and specialty medicines, with TEZSPIRE standing out as a product that could broaden the company's reach in inflammation if the latest trial data ultimately supports approval.
Closing price context
As of August 28, 2026, Amgen stock was last quoted at $436.99 on Nasdaq.
Fact box
Company: Amgen Inc.
ISIN: US0311621009
Ticker: AMGN
Exchange: Nasdaq
Price (as of August 28, 2026, 4:00 p.m. ET): $436.99 USD
Market cap: $236.25 billion
Sector / Industry: Biotechnology / Drug Manufacturers - General
Index membership: S&P 500
